Inflammatory bowel disease (IBD) and psoriasis (Ps) are common, chronic, immune- mediated
barrier diseases with shared inflammatory pathways. Current therapeutic interventions with
anti-cytokine antibodies (TNF-α, IL-23/IL-12) reflect the intent to disrupt specific pathways
of inflammatory immunopathology. Individual responses to biological treatment can be thereby
be exploited in a systems biology approach that employs a targeted mechanism of action (MOA)
to decipher molecular signatures of therapeutic responses in the context of a distinct
disease entity. Using a translational approach to investigate clinical and molecular
phenotypes during therapeutic interference with cytokine signaling and leukocyte trafficking,
the investigators aim to trace common and unique signatures of drug- and therapy-specific
responses.
Patients will undergo endoscopic evaluation of the mucosal surface and gastrointestinal wall
by conventional HD-colonoscopy, endoscopic ultrasound and confocal laser endomicroscopy prior
to and during specific therapies with biologicals. In parallel, mucosa samples will be
obtained to define molecular phenotypes during the course of therapy.
Phase:
N/A
Details
Lead Sponsor:
University Hospital Schleswig-Holstein University of Schleswig-Holstein